Remgro Limited
Registration number 1968/006415/06
ISIN ZAE000026480
JSE and A2X Share code REM
(“Remgro”)

SUMMARY OF MEDICLINIC GROUP LIMITED RESULTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2023
AND OUTLOOK FOR THE YEAR ENDING 31 MARCH 2024

INTRODUCTION

Given that Mediclinic Group Limited (“Mediclinic” or “Group”) is no longer listed due to the acquisition by Manta Bidco
Limited (a consortium made up of Remgro and MSC Mediterranean Shipping Company SA) of the entire issued share
capital of Mediclinic, there is no regulatory requirement for Mediclinic to release financial results. However, considering
the significant contribution by Mediclinic to Remgro’s results and intrinsic net asset value, Remgro believes that it is
appropriate to release a summary of Mediclinic’s 2024 half-year financial results and an outlook for the year ending
31 March 2024.

Remgro is therefore releasing a voluntary statement highlighting the salient points of Mediclinic’s performance for the six
months ended 30 September 2023 and an outlook for the year ending 31 March 2024. Mediclinic’s financial results,
including divisional results and reconciliations (“Mediclinic Abridged Results”), can be accessed at the following link on
Remgro’s website https://www.remgro.com/investor-centre/mediclinic-results/.

SUMMARY OF MEDICLINIC GROUP LIMITED RESULTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2023

SALIENT FEATURES

-     5% growth in Group revenue to $2 199m (1H23: $2 102m), a 5% increase in constant currency terms
-     Adjusted EBITDA decreased 4% to $285m (1H23: $297m), a 3% decrease in constant currency terms
-     Adjusted EBITDA margin decreased 8% to 13.0% (1H23: 14.2%)
      - Switzerland: 11.6% (1H23: 13.0%)
      - Southern Africa: 17.5% (1H23: 18.6%)
      - Middle East: 11.9% (1H23: 11.4%)
-     Adjusted earnings were flat at $81m (1H23: $81m)

GROUP RESULTS
                                                  Reported results                          Adjusted results1
                                            1H24         1H23                          1H24         1H23
                                              $'m         $'m      Variance2             $'m          $'m     Variance2
    Revenue                                 2 199       2 102            5%            2 199        2 102           5%
    Adjusted EBITDA3                                                                     285          297         (4)%
    Operating profit                          113           143         (21)%            150          157         (5)%
    Earnings4                                  69            98         (29)%             81           81           1%
    Headline earnings                          44            98         (55)%
    Net incurred debt5                                                                 1 536         1 432            7%
    Cash conversion6                                                                    63%           72%

1. The Group uses adjusted income statement reporting as non-IFRS measures in evaluating performance and to provide
   consistent and comparable reporting. Refer to the policy and “Reconciliations” section on pages 6-8 of the Mediclinic
   Abridged Results.
2. The percentage variances are calculated in unrounded dollar values and not in millions.
3. Adjusted earnings before interest, tax, depreciation and amortisation (“EBITDA”).
4. Earnings refers to earnings attributable to equity holders.
5. Net incurred debt reflects bank borrowings and excludes IFRS 16 lease liabilities.
6. Cash conversion is calculated as cash generated from operations as a percentage of adjusted EBITDA.

Adjusted results
The Group performance for the six months to 30 September 2023 was impacted by a weak performance in Switzerland,
partially offset by an outperformance in the Middle East. Group revenue was up 5% at $2 199m (1H23: $2 102m) and up
5% in constant currency terms. This result was driven by a 1.3% growth in inpatient admissions and a 3.9% growth in day
case admissions, partly offset, however, by lower average revenue per case due to mix changes and below-inflation tariff
increases. The strong growth in day case admissions confirms the ongoing outmigration of care trend which the Group is
addressing through its strategy of expanding across the continuum of care, entering new care settings outside of the hospital
environment.

Adjusted EBITDA was down 4% at $285m (1H23: $297m) and down 3% in constant currency terms. The Group’s adjusted
EBITDA margin was 13.0% (1H23: 14.2%). This decline reflected a softer revenue performance coupled with increased
employee and contractor costs in Switzerland as well as additional employee and energy costs in Southern Africa, the latter
due to increased loadshedding.

OUTLOOK FOR THE YEAR ENDING 31 MARCH 2024

Mediclinic continues to navigate the post-pandemic environment, which has introduced both macro-economic and sector-
specific challenges. With its diversified portfolio and expanding footprint across the continuum of care, Mediclinic remains
highly focussed on revenue growth and delivering operational and cost-efficiencies.

FY24 guidance
For the year to date, Mediclinic has seen a marginal improvement in group-wide performance in the second half of the
financial year ending 31 March 2024.

In Switzerland, Hirslanden expects to deliver FY24 revenue broadly in line with FY23 and an EBITDA margin around
13% (FY23: 14.7%).
Mediclinic Southern Africa expects to deliver FY24 revenue growth of around 6% and an EBITDA margin of around 18%
(FY23: 19.4%).
Mediclinic Middle East expects to deliver FY24 revenue growth of around 9% and an EBITDA margin of around 14%
(FY23: 14.4%).

Enquiries:
Remgro Investor Relations                                                                   investor.relations@remgro.com

The information contained in this voluntary announcement has not been reviewed or reported on by Remgro’s independent
external auditors.

Stellenbosch
15 March 2024

Sponsor
RAND MERCHANT BANK (a division of FirstRand Bank Limited)